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Abstract: Malassezia pachydermatis is a yeast that is frequently involved as a secondary/perpetuating factor in canine 
otitis externa, along with numerous species of bacteria. As a result, otitis is generally treated with topical therapies using 
combinations of antifungal, antimicrobial and anti-inflammatory agents. The evaluation of the combined effect of drugs 
included in commercially available products is therefore important. In vitro synergy of polymyxin B and miconazole has 
been demonstrated against one strain type of M. pachydermatis. This study was aimed at investigating the in vitro 
interactions of these two agents against five clinical strains of this yeast. A chequerboard broth microdilution method was 
employed. We observed a synergistic action against all strains tested (fractional inhibitory concentration index comprised 
between 0.2 and 0.4). Our results indicate a strong therapeutic value for the association of these antimicrobial agents in 
the treatment of canine otitis externa caused by M. pachydermatis. 
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 Canine otitis externa represents one of the most common 
diseases of multifactorial aetiology in veterinary practice [1]. 
Micro-organisms, including both bacteria and yeasts, are 
considered common perpetuating factors that can worsen and 
prevent the resolution of otitis [2]. Malassezia pachyder-
matis is the yeast isolated with the highest frequency from 
affected ears [3]. This organism is part of the commensal 
microflora of canine skin and ears, but it may become an 
opportunistic pathogen under favourable conditions, e.g. 
allergic, parasitic and immune-mediated diseases [1]. 
Topical therapy is the most popular and convenient way of 
treating canine otitis externa. Treatment usually involves the 
use of antibiotics, antifungals and anti-inflammatory agents, 
often included in a single formulation. A polyvalent product 
is indicated in first line treatment because bacteria and yeast 
are simultaneously present in a large number of cases [4]. In-
depth evaluation of the combined effect of drugs included in 
marketed products is therefore important. Among the 
possible combinations available, a commonly used product 
in clinical practice contains polymyxin B (PMX) as an 
antibiotic and miconazole nitrate (MCZ) as an antifungal. 
This combination has proven to be effective for the treatment 
of dogs with otitis externa complicated by a number of 
bacterial and yeast species [5, 6]. Such a positive response 
stems from the fact that PMX is effective against a broad 
variety of Gram-negative and, to a lesser extent, Gram-
positive bacteria, as well as having antifungal properties [7, 
8], while MCZ is active against several pathogenic fungi,  
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such as Candida albicans and M. pachydermatis and can 
also act upon certain Gram-positive bacteria [9, 10]. 
Moreover, a synergistic interaction in vitro between PMX 
and MCZ has been demonstrated against different species of 
bacteria frequently involved in canine otitis externa [11-13]. 
Synergy, in this context, can be defined as the increased 
effectiveness of multiple drugs that, in combination, are 
more efficient than the cumulative effects of the individual 
components [14]. Regarding M. pachydermatis, synergy has 
so far only been demonstrated against one type strain (M. 
pachydermatis CBS 1879) [12]. The aim of the present study 
was to evaluate the in vitro antifungal activity of the 
combination of PMX and MCZ against clinical strains of M. 
pachydermatis associated with canine otitis externa. 
 Five strains of M. pachydermatis from dogs with otitis 
externa, randomly selected from different regions of Italy, 
were investigated. Ears were sampled through the use of 
sterile cotton swabs, and yeasts were isolated on Sabouraud 
Dextrose Agar with chloramphenicol and gentamicine. 
Identification of these clinical isolates was based on 
macroscopic and microscopic characteristics [15]. All strains 
were examined for their in vitro susceptibility to PMX and 
MCZ as single substances and in combination. A modified 
CLSI (Clinical and Laboratory Standards Institute) M27-A3 
method [16] was employed. Christensen’s urea broth 
medium with Tween 80 and Tween 40 was used, instead of 
the RPMI 1640 medium suggested by the CLSI [16, 17], in 
order to meet the growth requirements of M. pachydermatis. 
Uniform yeast suspensions were prepared from 4-day-old 
colonies subcultured at 37°C on Sabouraud Dextrose Agar. 
Inoculum suspensions were adjusted by spectrophotometer, 
and the final yeast cell concentration was approximately  
1–5 × 105 cells/ml. Stock suspensions of MCZ (Sigma-
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Aldrich, Taufkirchen, Germany) and PMX (Sigma-Aldrich) 
were prepared in dimethyl sulfoxide. Synergy trials were 
performed as chequerboard interactions in 96-well plates. 
Yeasts were added to a twofold serial dilution of a single 
antibiotic agent or in combination with an identical dilution 
of the other antibiotic agent. Plates were incubated at 37°C 
and analysed at 48 h after inoculation. Concentrations tested 
in combination consisted of equal molar concentrations of 
PMX and MCZ [13]. They varied from 34.38 mg/l PMX 
combined with 11.72 mg/l MCZ (corresponding to 24.81 x 
10-6 mol/l of each drug) to 0.54 mg/l PMX combined with 
0.18 mg/l MCZ (corresponding to 0.39 x 10-6 mol/l of each 
drug). The minimum inhibitory concentration (MIC) was 
read as the lowest concentration of antimicrobial substance 
which inhibited visible growth, as assessed by using a 
spectrophotometer (630 nm filter). Each strain was tested on 
three separate occasions to verify the reproducibility of the 
results obtained [18]. The fractional inhibitory concentration 
index (FICi) was calculated as follows: FIC of drug A (MIC 
of drug A in combination/ MIC of drug A alone) + FIC of 
drug B (MIC of drug B in combination/MIC of drug B 
alone). FICi was interpreted as follows: <  0. 5 = synergy; > 
0.5 – 4 = no interaction; > 4 = antagonism [19]. 
 MICs of MCZ for M. pachydermatis isolates ranged from 
1.46–5.86 mg/l; MIC of PMX for all strains tested was 4.3 
mg/l. If both antimicrobial agents were used in combination, 
the susceptibility of M. pachydermatis was altered to an MIC 
of 0.18 mg/l (MCZ) and 0.54 (PMX) mg/l, with 
corresponding FICi<0.50, which indicates a synergistic 
response, as shown in Fig. (1). Results of the susceptibility 
tests are summarized in Table 1. 
 As mentioned above, synergy is said to occur when the 
combination of drugs results in a more efficient response 
than the cumulative effects of the individual components 
[14]. In the case of the combination of PMX and MCZ, 
 
Fig. (1). Test showing synergy between miconazole (MCZ) and polymyxin B (PMX) in the strain of M. pachydermatis VMT 645 – 
Concentration varied from 34.38 mg/l PMX combined with 11.72 mg/l MCZ to 0.54 mg/l PMX combined with 0.18 mg/l MCZ- Wells with 
yeast growth are highlighted (blue circles). 
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synergy occurs because PMX is able to increase the efficacy 
of hydrophobic antibiotics, such as MCZ, by facilitating 
penetration so that MCZ can more readily reach the 
intracellular space in order to carry out its action [20]. MCZ 
is known to inhibit the synthesis of ergosterol, a bioregulator 
of membrane integrity in fungal cells [21]. MCZ can also 
function in its antifungal role by inducing reactive oxygen 
species which results in fungal cell death [22, 23]. 
 Up until now, synergy between PMX and MCZ has been 
demonstrated against different bacterial species often 
involved in canine otitis externa, such as Staphylococcus 
aureus, Pseudomonas aeruginosa and Escherichia coli [11, 
12], but in most cases experiments have been conducted on 
reference strains. Moreover, Pietschmann et al. (2013) have 
recently shown an in vitro synergy of PMX and MCZ against 
field strains (i.e. strains sampled from dogs with otitis 
externa) of E. coli and P. aeruginosa. Regarding fungi, 
synergy of PMX and MCZ has also been demonstrated 
against Candida albicans [24] and M. pachydermatis. 
However, with reference to M. pachydermatis, data has only 
been collected for one strain, which was, furthermore, a 
reference strain coming from a fungal collection  
(M. pachydermatis CBS 1879) [12]. Our data confirm that a 
synergistic interaction of PMX and MCZ exists against field 
strains of M. pachydermatis. Although further studies on a 
larger number of strains are necessary for confirmation, these 
findings support the rationale for applying PMX and MCZ in 
combination for the treatment of canine otitis externa caused 
by M. pachydermatis. In addition, the fact that these two 
drugs display a synergistic effect may enable a reduction of 
their dosage and of the length of treatment, which, in turn, 
may reduce the risk of the development of drug resistance. 
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